ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the sale, the director now owns 210,346 shares in the company, valued at approximately $2,589,359.26. This represents a 19.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $11.10, for a total transaction of $555,000.00.
• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.56, for a total value of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY traded up $0.21 during mid-day trading on Tuesday, hitting $12.52. The stock had a trading volume of 1,193,445 shares, compared to its average volume of 1,437,551. The firm’s 50 day moving average is $12.48 and its 200 day moving average is $13.12. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -24.55 and a beta of 0.99. ARS Pharmaceuticals, Inc. has a twelve month low of $6.26 and a twelve month high of $18.51.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Leerink Partners upped their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Finally, Raymond James increased their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, ARS Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $26.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC grew its stake in ARS Pharmaceuticals by 189.7% during the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock valued at $1,618,000 after acquiring an additional 73,127 shares in the last quarter. First Turn Management LLC acquired a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth approximately $8,603,000. Royce & Associates LP grew its position in shares of ARS Pharmaceuticals by 7.1% in the third quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock valued at $10,026,000 after purchasing an additional 45,755 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at approximately $2,584,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in ARS Pharmaceuticals by 766.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after buying an additional 207,456 shares in the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.